Galena Biopharma (GALE) PT Lowered at Needham & Company But Still Sees Shares Doubling
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- US stock futures rise after previous session's selloff
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Supermicro probe finds no senior management link to export violations
- SpaceX shares fall as second lockup period ends
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
Noble Financial Maintains 'Buy' Rating on Galena (GALE); NeuVax Enrollment Nearly Complete
March 10, 2015 12:18 PM EDTNoble Financial affirms Galena Biopharma (Nasdaq: GALE) at Buy with a price target of $5 following Q4 results and update issued last week.
Analyst Rahul Jasuja offered the following key points:
NEUVAX Phase 3 Trial (PRESENT): target enrollment of 700 patients achieved; plans to over-enroll beyond 700... MoreRoth Affirms Galena Biopharma (GALE) at 'Buy' Following Q4 Report; Still Sees FY15/FY16 as Busy Time Frame
March 6, 2015 8:42 AM ESTRoth Capital reiterates its Buy rating and $8 price target on Galena Biopharma (Nasdaq: GALE) following Q4, FY14 results reported Thursday night.
Analyst Joseph Pantginis noted that Galena's FY14 revenue of $9.32 million and loss of $0.31 per share compare with the firm's outlook calling for revenue of $8.5 million and loss of $0.35 per share.
Pantginis offered the following post-report commentary: 2015 represents a... More
Galena Biopharma (GALE) Reports Q4 Loss Per Share of 6c, Reiterates FY15 Rev. Guidance
March 5, 2015 4:21 PM ESTGalena Biopharma (NASDAQ: GALE) reported Q4 EPS of ($0.06), may not compare to the analyst estimate of ($0.11). Revenue for the quarter came in at $3.2 million versus the consensus estimate of $2.58 million.
Galena reiterated 2015 net revenue guidance between $15-$18 million for the combined commercial... More
